Zinger Key Points
- IperionX secured a $99M DoD contract to supply U.S.-made titanium for defense applications.
- Initial orders will deliver high-performance fasteners made at its Virginia facility, supporting local skilled jobs.
- Get access to the leaderboards pointing to tomorrow’s biggest stock movers.
IperionX Limited IPX shares surged Thursday after the company secured a major U.S. Department of Defense contract to supply domestically produced titanium parts for military use.
The $99 million Small Business Innovation Research (SBIR) Phase III Indefinite Delivery, Indefinite Quantity (IDIQ) agreement enables the Pentagon to order titanium components directly from IperionX.
The contract permits U.S. defense agencies to commission task-specific orders as part of the “Low-Cost Domestic Titanium for Defense Applications” effort.
Early task orders will involve high-performance titanium fasteners manufactured at IperionX’s Virginia campus using proprietary technologies. The project supports skilled local jobs while advancing U.S. defense readiness.
Also Read: Top 2 Materials Stocks That Are Ticking Portfolio Bombs
The agreement aligns with federal priorities to boost the supply of strategic materials from domestic sources. Future task orders could include advanced aerospace parts, positioning IperionX as a long-term supplier for military-grade titanium.
“Securing this Phase III contract is a pivotal milestone for IperionX,” said Anastasios (Taso) Arima, the company’s CEO. “It validates the performance of our technologies and underscores the Department of Defense’s commitment to reshore an all-American titanium supply chain.”
Relevant ETFs include SPDR S&P Aerospace & Defense ETF XAR and iShares U.S. Aerospace & Defense ETF ITA.
Price Action: IPX shares are trading 23.79% higher at $30.23 at Thursday’s last check.
Read Next:
Edge Rankings
Price Trend
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.